Citadel Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Citadel Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,400	Closed	-$973K	–	14449
2026 Q1	$973K	Sell	30,400 -28,900	-49%	-$941K	﹤0.01%	7717
2025 Q4	$2.08M	Buy	59,300 +25,100	+73%	+$913K	﹤0.01%	5833
2025 Q3	$973K	Sell	34,200 -2,300	-6%	-$55.1K	﹤0.01%	7586
2025 Q2	$661K	Sell	36,500 -49,400	-58%	-$901K	﹤0.01%	7981
2025 Q1	$1.76M	Sell	85,900 -18,000	-17%	-$400K	﹤0.01%	5779
2024 Q4	$2.67M	Buy	103,900 +100,300	+2,786%	+$2.13M	﹤0.01%	5048
2024 Q3	$59.8K	Buy	3,600 +400	+13%	+$6.92K	﹤0.01%	11708
2024 Q2	$61.5K	Buy	+3,200	New	+$64.2K	﹤0.01%	11536

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Citadel Advisors's NAMS Position: Q2 2026 in Review

Citadel Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 9.3% in Q2 2026, selling an estimated $2.18M and leaving 645,805 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Citadel Advisors first reported a position in NAMS in Q3 2023 and has held it in 12 quarters since. The position peaked at $25.1M in Q4 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Citadel Advisors held 645,805 shares of NewAmsterdam Pharma worth $21.9M as of Q2 2026.
Citadel Advisors sold 66,259 NewAmsterdam Pharma shares in Q2 2026, an estimated $2.18M.
NewAmsterdam Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2448 holding.
Citadel Advisors first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 12 quarters since.
Citadel Advisors's NewAmsterdam Pharma position peaked at $25.1M in Q4 2024.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.